DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Merck’s Verubecestat Fails in Mild to Moderate AD: What Now?

On February 14, 2017, Merck announced it was halting the Phase III EPOCH study of its BACE inhibitor verubecestat in mild to moderate Alzheimer’s disease (AD) due to lack of efficacy. In DRG’s current AD forecast, we assume the drug is the first DMT to market and accounts for 30% of the total AD market in 2025. This failure will lead us to reconsider our 2025 outlook; here, we present some top-line thoughts and considerations.

How will the February 2017 termination of the Phase III EPOCH study of Merck’s BACE inhibitor verubecesat in mild to moderate AD impact the market outlook through 2025? Download this white paper for topline thoughts and considerations on what this means for verubecestat, other late-phase BACE inhibitors, and the DMT market overall.